Stemcentrx, Inc.

stemcentrx.com

Founded in 2008, Stemcentrx combines state-of-the-art research and GMP manufacturing capabilities. This has allowed us to advance from target discovery in our laboratory to treating patients in clinical trials at an accelerated pace. We are investigating many of the largest and most lethal cancers through our proprietary platforms that identify cancer stem cells, discover novel targets, engineer and manufacture antibodies and antibody drug conjugates. Our mission is to develop therapies that cure and significantly improve survival for cancer patients. We are pioneering new approaches to eliminate cancer stem cells, which initiate and perpetuate tumors. Stemcentrx has assembled a talented and motivated team committed to this mission. We are recruiting people with world-class expertise in their practice, versatility, high energy and an entrepreneurial spirit.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ACORDA THERAPEUTICS ANNOUNCES $16.5M AWARD AND ROYALTY/SUPPLY RELIEF IN AMPYRA® ARBITRATION CASE

Acorda Therapeutics, Inc. | October 17, 2022

news image

Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA. Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, ...

Read More

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

news image

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

news image

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More

Industrial Impact

CANOPY BIOSCIENCES LAUNCHES NEXT-GENERATION CHIPCYTOMETRY™ INSTRUMENT FOR SPATIAL BIOLOGY WITH SUB-CELLULAR RESOLUTION

Canopy Biosciences | March 04, 2022

news image

Canopy Biosciences, a Bruker Company, announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new benchtop CellScape s...

Read More
news image

MedTech

ACORDA THERAPEUTICS ANNOUNCES $16.5M AWARD AND ROYALTY/SUPPLY RELIEF IN AMPYRA® ARBITRATION CASE

Acorda Therapeutics, Inc. | October 17, 2022

Acorda Therapeutics, Inc. announced that a three-judge arbitration panel has issued a final decision in a dispute with Alkermes PLC regarding licensing royalties relating to AMPYRA. Acorda was awarded $15 million plus prejudgment interest of $1.5 million from Alkermes. In addition, as a result of the panel’s ruling, Acorda will no longer have to pay Alkermes any royalties on net sales for license and supply of AMPYRA, and Acorda is now free to use alternative sources for supply of AMPYRA, ...

Read More
news image

Industrial Impact

ADAPTIVE BIOTECHNOLOGIES ANNOUNCES NEW DATA DEMONSTRATING IMMUNOSEQ® TECHNOLOGY CAN IDENTIFY T-CELL RECEPTORS ASSOCIATED WITH CROHN’S DISEASE

Adaptive Biotechnologies | February 19, 2022

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, presented data on T-cell receptor (TCR) sequences associated with Crohn’s disease (CD) during an oral presentation today at the 17th Congress of European Crohn’s and Colitis Organisation (ECCO) being held virtually February 16-19. The study identified and characterized TCR sequences associ...

Read More
news image

NORTHWEST BIOTHERAPEUTICS ANNOUNCES THE COMPLETION OF FINANCING ON A FAVORABLE TERMS FOR APPROXIMATELY $8 MILLION

Northwest Biotherapeutics | August 12, 2020

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further ...

Read More
news image

Industrial Impact

CANOPY BIOSCIENCES LAUNCHES NEXT-GENERATION CHIPCYTOMETRY™ INSTRUMENT FOR SPATIAL BIOLOGY WITH SUB-CELLULAR RESOLUTION

Canopy Biosciences | March 04, 2022

Canopy Biosciences, a Bruker Company, announced the commercial launch of the CellScapeTM system, the next generation in ChipCytometryTM instrumentation, advancing the cutting-edge for quantitative in situ spatial phenotyping. ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumor microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease. The new benchtop CellScape s...

Read More